Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 237,284,664 papers from all fields of science
Search
Sign In
Create Free Account
ertumaxomab
Known as:
Anti-CD3 x anti-HER-2-neu Bispecific Monoclonal Antibody
, CD3-HER2neu MOAB
, MOAB anti-CD3 x anti-HER-2-neu
A murine monoclonal antibody with two antigen-recognition sites: one for CD3, an antigen expressed on mature T cells, and one for HER-2-neu, a tumor…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
Monoclonal Antibodies
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Abstract P3-14-21: Phase II Study of Single Agent Trifunctional Antibody Ertumaxomab (Anti-HER-2 & Anti-CD3) in HER-2 Low Expressing Hormone-Refractory Advanced Breast Cancer Patients (ABC)
F. Cardoso
,
L. Dirix
,
+8 authors
J. Cortes
2010
Corpus ID: 72384895
Background: Ertumaxomab is an intact bispecific trifunctional antibody targeting HER-2 and CD3 as well as activating Fc…
Expand
2010
2010
Langzeit-Tumorstabilisation einer Her-2-neu positiven, metastasierten Mammakarzinompatientin unter Lapatinib und Capecitabin
T. Idris
,
E. Hartner
,
P. Krippl
,
U. Lang
,
E. Petru
2010
Corpus ID: 71689729
2010
2010
Langzeitüberleben einer Her-2-neu-positiven Mammakarzinompatientin unter Lapatinib und Capecitabin trotz zahlreichen Vortherapien
T. Idris
,
E. Hartner
,
P. Krippl
,
U. Lang
,
E. Petru
2010
Corpus ID: 80108309
2010
2010
Abstract 3481: Establishment of preclinical models to identify clinically useful combinations of trifunctional antibodies with chemotherapy
K. Dettmar
,
J. Atz
,
C. Lindemann
,
P. Schroeder
,
A. Eberhardt
,
M. Kluge
2010
Corpus ID: 71889863
Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC The trifunctional bispecific antibodies…
Expand
2009
2009
Factor Receptor 2 Cells That Express Low Levels of Human Epidermal Growth The Trifunctional Antibody Ertumaxomab Destroys Tumor
M. Jäger
,
A. Schoberth
,
P. Ruf
2009
Corpus ID: 78405946
Abstract Humanepidermalgrowthfactorreceptor2(HER2/neu)isanimportant target for the treatment of the breast cancers inwhich it is…
Expand
2008
2008
Highly effective elimination of low Her2 (1+) expressing tumor cells by trifunctional antibody ertumaxomab
M. Jaeger
,
P. Ruf
,
J. Hess
,
A. Schoberth
,
H. Lindhofer
2008
Corpus ID: 201991778
2405 Her2 has become an important therapeutic target for antibody-directed treatment of breast cancer with overexpressed Her2 (3…
Expand
2006
2006
Phase I Trial of theTrifunctional Anti-HER 2 Anti-CD 3 Antibody Ertumaxomab in Metastatic Breast Cancer
P. Kiewe
,
S. Kahlert
,
+7 authors
A. Untch
2006
Corpus ID: 35770414
Purpose: Ertumaxomab is an intact bispecific antibody targeting HER2/neu and CD3 with selective binding to activatory Fcg type I…
Expand